The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).
Oliver Edgar Bechter
No relevant relationships to disclose
Nicole Unger
No relevant relationships to disclose
Ivan Borbath
No relevant relationships to disclose
Sergio Ricci
No relevant relationships to disclose
Tsann-Long Hwang
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Jiri Tomasek
No relevant relationships to disclose
Hussein Raef
No relevant relationships to disclose
Sudsawat Laohavinij
Research Funding - Novartis
Lisa JeanLouis
Employment or Leadership Position - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Sotirios G. Stergiopoulos
Employment or Leadership Position - Novartis
Marianne E. Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer